Design And Evaluation Of Transdermal Patches Of Vildagliptin Using Nanotechnology

Abstract

The current study focuses on the design and evaluation of transdermal patches containing Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. Oral administration of Vildagliptin often leads to gastrointestinal side effects and undergoes first-pass metabolism, reducing its bioavailability. To overcome these limitations, nanotechnology-based transdermal drug delivery systems were developed to ensure sustained and controlled drug release, improve patient compliance, and enhance bioavailability. Nanoparticles of Vildagliptin were prepared using suitable polymeric carriers and incorporated into matrix-type transdermal patches using the solvent casting method. The prepared patches were evaluated for physicochemical parameters such as thickness, tensile strength, moisture content, drug content uniformity, and folding endurance. In vitro drug release studies and skin permeation analysis were also conducted using Franz diffusion cells. The results indicated that nanotechnology-assisted transdermal patches provided uniform drug release over an extended period with improved permeation efficiency. This approach holds promise for the effective and non-invasive delivery of Vildagliptin for better glycemic control in diabetic patients.